Co-Founder And Director
CurrentTregeutix (pronounced ti·rəˈgyoo·tiks or trəˈgyoo·tiks) is advancing unique, first-in-kind antigen-specific immunotherapeutic approaches by addressing how microbiota derived antigen cross-reactivity maintains full and complete repertoire of Foxp3+ regulatory T cells (Tregs) essential for health.